The estimated Net Worth of Eva M. Jack is at least $62.4 Tisíc dollars as of 14 September 2020. Ms. Jack owns over 35,248 units of Mersana Therapeutics Inc stock worth over $62,389 and over the last 7 years she sold MRSN stock worth over $0. In addition, she makes $0 as Chief Business Officer at Mersana Therapeutics Inc.
Eva has made over 1 trades of the Mersana Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 35,248 units of MRSN stock worth $53,929 on 14 September 2020.
The largest trade she's ever made was exercising 35,248 units of Mersana Therapeutics Inc stock on 14 September 2020 worth over $53,929. On average, Eva trades about 7,050 units every 0 days since 2018. As of 14 September 2020 she still owns at least 35,248 units of Mersana Therapeutics Inc stock.
You can see the complete history of Ms. Jack stock trades at the bottom of the page.
Eva M. Jack serves as Chief Business Officer of the Company. Previously, from 2012 to 2013, she served as a consultant to various biotech companies and investors on business and financing strategies. Before that, she served as Chief Business Officer of Pulmatrix from 2010 to 2012. Before Pulmatrix, she spent six years at MedImmune, the worldwide biologics unit of AstraZeneca, as Managing Director of MedImmune Ventures, overseeing investments in private biotechnology companies, and as a Director in MedImmune’s Business Development group. Earlier in her career, Ms. Jack held a variety of positions at Intel Corp. Ms. Jack received a B.A. from the University of Virginia and a master’s in health sciences from The Johns Hopkins University.
Eva Jack is 52, she's been the Chief Business Officer of Mersana Therapeutics Inc since 2013. There are 13 older and 7 younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.
Eva's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include: